On September 19, 2017 Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer, reported that data for its drug candidate CB-839, an orally bioavailable glutaminase inhibitor, will be presented at the 32nd Annual Meeting of the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper), which is being held from November 10 to November 12, 2017, at the Gaylord National Hotel & Convention Center in National Harbor, Maryland (Press release, Calithera Biosciences, SEP 19, 2017, View Source [SID1234520571]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Clinical results to be presented include data from Calithera’s trial of CB-839 dosed in combination with Opdivo (nivolumab) in patients with advanced melanoma, renal cell carcinoma, or non-small cell lung cancer. The trial is the subject of a clinical collaboration with Bristol-Myers Squibb.

A phase 1/2 study of CB-839, a first-in-class glutaminase inhibitor, combined with nivolumab in patients with advanced melanoma, renal cell carcinoma or non-small cell lung cancer.
Presenter: Dr. Funda Meric-Bernstam, MD Anderson Cancer Center
Session: Clinical Trials: Novel Combinations
Session Date and Time: November 11, 2017, 3:30 p.m. – 6:00 p.m. ET